bluebird bio (BMV:BLUE *) - Aktienkurs, Nachrichten und Analyse

BLUE * Aktienübersicht

bluebird bio, Inc. ist ein Biotechnologieunternehmen, das Gentherapien für die Heilung schwerer genetischer Krankheiten in den Vereinigten Staaten erforscht, entwickelt und vermarktet. Mehr Details

BLUE * grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	0/6
Dividenden	0/6

Belohnungen

94.9% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes jährliches Umsatzwachstum 41.53%

Risikoanalyse

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

Hat weniger als 1 Jahr Cash Runway

Negatives Eigenkapital

Aktien sind hochgradig illiquide

+ 3 mehr Risiken

bluebird bio, Inc. Wettbewerber

Generation Bio

NasdaqGS:GBIO

US$93.5m

BioAtla

NasdaqGM:BCAB

US$80.3m

Coya Therapeutics

NasdaqCM:COYA

US$108.6m

X4 Pharmaceuticals

NasdaqCM:XFOR

US$57.2m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für bluebird bio
Historische Aktienkurse
Aktueller Aktienkurs	US$10.00
52-Wochen-Hoch	US$25.00
52-Wochen-Tief	US$9.50
Beta	0.80
11 Monat Veränderung	0%
3 Monate Veränderung	-17.36%
1 Jahr Veränderung	n/a
33 Jahre Veränderung	-95.58%
5 Jahre Veränderung	-99.28%
Veränderung seit IPO	-99.57%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	BLUE *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie BLUE * im Vergleich zur Branche MX Biotechs abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie BLUE * im Vergleich zum MX Markt abgeschnitten hat.

Preisvolatilität

Is BLUE *'s price volatile compared to industry and market?
BLUE * volatility
BLUE * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiler Aktienkurs: BLUE *Der Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von BLUE * im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1992	282	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc. ist ein Biotechnologieunternehmen, das Gentherapien für die Heilung schwerer genetischer Krankheiten erforscht, entwickelt und in den Vereinigten Staaten vermarktet. Zu den Produktkandidaten des Unternehmens für schwere Erbkrankheiten gehören ZYNTEGLO (betibeglogene autotemcel) zur Behandlung der transfusionsabhängigen ß-Thalassämie, lovotibeglogene autotemcel zur Behandlung der Sichelzellenkrankheit (SCD) und SKYSONA (elivaldogene autotemcel) zur Behandlung der zerebralen Adrenoleukodystrophie. Zu den klinischen Entwicklungsprogrammen gehören HGB-205, HGB-206 und HGB-210 zur Untersuchung der Sicherheit und Wirksamkeit von lovo-cel bei der Behandlung von Patienten mit SCD sowie HGB-204, HGB-205, HGB-207 und HGB-212 zur Untersuchung der Sicherheit und Wirksamkeit von beti-cel bei der Behandlung von Patienten mit ß-Thalassämie.

bluebird bio, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von bluebird bio im Vergleich zum Marktanteil des Unternehmens?
BLUE * grundlegende Statistiken
Marktanteil	Mex$1.49b
Gewinn(TTM)	-Mex$6.07b
Umsatz(TTM)	Mex$1.10b

1.4x

Kurs-Umsatz-Verhältnis

-0.2x

Kurs-Gewinn-Verhältnis

Ist BLUE * zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
BLUE * Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$53.12m
Kosten der Einnahmen	US$78.78m
Bruttogewinn	-US$25.66m
Sonstige Ausgaben	US$267.16m
Umsatz	-US$292.82m

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.51
Bruttomarge	-48.31%
Nettogewinnspanne	-551.25%
Schulden/Eigenkapital-Verhältnis	-1,394.4%

Wie hat sich BLUE * auf lange Sicht entwickelt?

Historische Performance und Vergleiche

BLUE * Aktienübersicht

Belohnungen

Risikoanalyse

bluebird bio, Inc. Wettbewerber

NasdaqGS:GBIO

US$93.5m

NasdaqGM:BCAB

US$80.3m

NasdaqCM:COYA

US$108.6m

NasdaqCM:XFOR

US$57.2m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023)

New major risk - Revenue and earnings growth

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023)

New major risk - Revenue and earnings growth

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

Chief Medical Officer recently sold Mex$176k worth of stock

Chief Medical Officer recently sold Mex$176k worth of stock

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Less than half of directors are independent

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Less than half of directors are independent

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold Mex$1.6m worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold Mex$1.9m worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

Chief Regulatory Officer recently sold Mex$140k worth of stock

Less than half of directors are independent

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Chief Commercial Officer recently sold Mex$226k worth of stock

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

Less than half of directors are independent

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

Less than half of directors are independent

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

Insider recently sold Mex$80k worth of stock

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022

Insider recently sold Mex$637k worth of stock

Less than half of directors are independent

Erträge & Einnahmen